晚期疗法诱导溃疡性结肠炎缓解的有效性与安全性:更新系统评价与网状Meta分析
乌帕替尼在临床缓解和内镜改善方面相对疗效最高(高置信度),抗p19抑制剂安全性最优但置信度较低。
要点
- 乌帕替尼诱导临床缓解相对疗效最高(RR 6.90,高置信度)
- 抗p19抑制剂不良事件安全性最优,但证据置信度较低
- 初治与经治患者疗效排名不同,需分层选择方案
核心结论
- 乌帕替尼对初治和经治中重度溃疡性结肠炎患者的诱导临床缓解和内镜改善均具有高效力。
- 新型疗法如obefazimod和皮下古塞奇尤单抗可能为高效替代选择。
- 抗p19抑制剂提供有利的安全性特征,但安全性估计的置信度较低。
研究设计与样本
- 系统评价与网状Meta分析,检索MEDLINE、Embase和Cochrane CENTRAL。
- 采用频率随机效应模型进行配对Meta分析和网状Meta分析,使用CINeMA框架评估置信度。
主要发现
- 乌帕替尼临床缓解RR 6.90(95% CI 3.54-12.45;P-score 0.95;高置信度)。
- 乌帕替尼内镜改善RR 5.29(95% CI 3.38-8.28;P-score 0.97;中等置信度)。
- 初治患者中obefazimod和乌帕替尼疗效最高,经治患者中乌帕替尼、乌司奴单抗和托法替布排名最高。
- 抗p19抑制剂(risankizumab、皮下古塞奇尤单抗、mirikizumab)在严重不良事件和导致停药的不良事件方面安全性特征最有利。
关键数值与推荐
- 主要结局为临床缓解;次要结局包括内镜改善、严重不良事件、导致停药的不良事件和严重感染。
- 分析按既往晚期疗法暴露分层。
临床怎么用
- 初治和经治中重度溃疡性结肠炎诱导治疗可优先考虑乌帕替尼以获得高临床缓解和内镜改善。
- 关注安全性时可考虑抗p19抑制剂,但需注意安全性证据置信度较低。
- 初治患者可考虑obefazimod作为高效替代,经治患者可考虑乌司奴单抗或托法替布。
局限性
- 安全性估计的置信度较低。
- 头对头试验有限,比较依赖网状Meta分析间接证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Advanced therapies (ATs) are central to the management of moderate-to-severe ulcerative colitis (UC). The expanding therapeutic landscape and limited head-to-head trials necessitate updated comparative effectiveness analyses. We performed a systematic review and network meta-analysis (NMA) to assess the efficacy and safety of ATs as induction therapy for UC. METHODS: We searched MEDLINE, Embase, and Cochrane CENTRAL. We included phase 3 randomized controlled trials evaluating approved ATs or agents in late-stage development for induction therapy in moderate-to-severe UC. Pairwise meta-analyses and NMA were conducted using a frequentist random-effects model. Confidence was evaluated using the CINeMA framework. The primary outcome was clinical remission; secondary outcomes included endoscopic improvement, serious adverse events (SAEs), adverse events leading to discontinuation (AELDs), and serious infections. Analyses were stratified by prior exposure to ATs. RESULTS: Thirty-three induction trials involving 17 therapies, were included. Upadacitinib demonstrated the highest relative efficacy for clinical remission (RR 6.90; 95% CI 3.54-12.45; P-score 0.95; high confidence) and endoscopic improvement (RR 5.29; 95% CI 3.38-8.28; P-score 0.97; moderate confidence). In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest. Anti-p19 inhibitors, including risankizumab, subcutaneous guselkumab, and mirikizumab, were associated with the most favorable safety profiles for SAEs and AELDs, although confidence in safety estimates was lower. CONCLUSIONS: Upadacitinib has high efficacy for induction of clinical remission and endoscopic improvement in AT-naïve and AT-experienced patients. Novel therapies, like obefazimod and guselkumab subcutaneous, may represent highly effective alternatives. Anti-p19 inhibitors offer a favorable safety profile.
引用
- Olivera PA, Lasa JS, Singh S, et al. EFFICACY AND SAFETY OF ADVANCED THERAPIES AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. Clin Gastroenterol Hepatol. 2026. PMID: 42838315. doi:10.1016/j.cgh.2026.09.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。